New Research Points to miR-25 as a Therapeutic Target for Heart Failure | GenomeWeb

A group led by researchers from Sanford-Burnham Medical Research Institute published data last week showing that inhibiting a single microRNA, miR-25, could stop the progression of heart failure in a mouse model while boosting the animals' cardiac function and survival.

The findings implicate miR-25 as a key player in the decline of cardiac function during heart failure and demonstrate its promise as a therapeutic target for the condition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.